Somatic activating mutations in the PIK3CA gene were found in more than 10% of high-grade serous and 40% of clear cell ovarian carcinomas [50], and constitutive activation of the PI3K/Akt/mTOR axis is known to confer drug resistance to many types of cancer. The gene discussed is MTOR; the disease is ovarian clear cell cancer.